Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Type I gastric carcinoids (TIGCs) are neuroendocrine neoplasms arising from enterochromaffin-like cells in atrophic body gastritis. Data regarding their evolution in prospective series are scarce, thus treatment and follow-up are not codified. Our aim was to evaluate clinical outcome and recurrence in TIGCs managed by endoscopic approach. METHODS: 33 patients (24 females; median age 65 years, range 23-81) were included and managed through endoscopic follow-up every 6-12 months, with lesion removal and multiple gastric biopsies. Baseline clinical and histological features were analyzed as risk factors by Cox regression. RESULTS: At diagnosis, 7 tumors were intramucosal carcinoids and 26 were polyps (median diameter 5 mm, range 2-20), multiple in 17 patients. Associated severe atrophy was present in 21 cases (63.6%), while mild atrophy was found in 6 cases (18.2%). During a 46-month median follow-up, survival was 100% and no metastases occurred. One patient developed a less-differentiated carcinoid that was radically treated by surgery. 21 patients (63.6%) had recurrence after a median of 8 months, 14 of these (66.6%) had a second recurrence after a median of 8 months following the previous carcinoid removal. Median recurrence-free survival was 24 months. Neither clinical nor biochemical recurrence-predicting factors were found. CONCLUSIONS: Although about 60% of TIGCs had recurrence after endoscopic resection, endoscopic management may be considered safe and effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Small NETs are typically asymptomatic and often diagnosed incidentally.”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Small NETs are typically asymptomatic and often diagnosed incidentally.”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These usually appear as small to tiny nodules <10 mm and are most often found at the gastric corpus or fundus; they are typically well-differentiated with an indolent course.85–88”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These usually appear as small to tiny nodules <10 mm and are most often found at the gastric corpus or fundus; they are typically well-differentiated with an indolent course.85–88”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“These usually appear as small to tiny nodules <10 mm and are most often found at the gastric corpus or fundus; they are typically well-differentiated with an indolent course.85–88”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [87]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and Grading of Gastritis: The Updated Sydney System
Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199610000-00001 · Cited by 5,185
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
de Vries, A. C., van Grieken, N. C. T., Looman, C. W. N., Casparie, M. K., de Vries, E., Meijer, G. A., & Kuipers, E. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.071 · Cited by 848
Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy
Davis, C. J., Mostofi, F. K., & Sesterhenn, I. A. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199501000-00001 · Cited by 599
Gastric Carcinoids and Neuroendocrine Carcinomas: Pathogenesis, Pathology, and Behavior
Rindi, G., Bordi, C., Rappel, S., La Rosa, S., Stolte, M., & Solcia, E. (1996) · World Journal of Surgery · doi:10.1007/s002689900026 · Cited by 433
Self-citationHistopathological Classification of Nonantral Gastric Endocrine Growths in Man
Solcia, E., Bordi, C., Creutzfeldt, W., Dayal, Y., Dayan, A. D., Falkmer, S., Grimelius, L., & Havu, N. (1988) · Digestion · doi:10.1159/000199786 · Cited by 361
Self-citationRindi, G., Azzoni, C., Rosa, S. L., Klersy, C., Paolotti, D., Rappel, S., Stolte, M., Capella, C., Bordi, C., & Solcia, E. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70174-5 · Cited by 354
Self-citationPernicious anemia and subsequent cancer. A population-based cohort study
Hsing, A. W., Hansson, L.-E., McLaughlin, J. K., Nyren, O., Blot, W. J., Ekbom, A., & Fraumeni, J. F. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3<745::aid-cncr2820710316>3.0.co;2-1 · Cited by 310
Borch, K., Ahrén, B., Ahlman, H., Falkmer, S., Granérus, G., & Grimelius, L. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000167862.52309.7d · Cited by 287
A. KOKKOLA, S.-M. S. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850166266 · Cited by 229
Research works printed but not linked: 40
- Delle Fave G, Capurso G, Milione M, et al: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 2005; 19: 659- 673.
- Modlin IM, Lye KD, Kidd M: A 50-year anal- ysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23-32.
- Yao JC, Hassan M, Phan A, et al: One hun- dred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
- Annibale B, Azzoni C, Corleto VD, et al: Atrophic body gastritis patients with entero- chromaffin-like cell dysplasia are at in- creased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepa- tol 2001; 13: 1449-1456.
- Rindi G, Azzoni C, La Rosa S, et al: ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evalu- ation by pathological analysis. Gastroenter- ology 1999; 116: 532-542.
- Solcia E, Bordi C, Creutzfeldt W, et al: Histo- pathological classification of nonantral gas- tric endocrine growths in man. Digestion 1998; 41: 185-200.
- Burkitt MD, Pritchard DM: Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24: 1305-1320.
- Granberg D, Wilander E, Stridsberg M, et al: Clinical symptoms, hormone profiles, treat- ment, and prognosis in patients with gastric carcinoids. Gut 1998; 24: 223-228.
- Borch K, Ahrén B, Ahlman H, et al: Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64-73.
- Gladdy RA, Strong VE, Coit D, et al: Defin- ing surgical indications for type I gastric car- cinoid tumor. Ann Surg Oncol 2009; 16: 3154-3160.
- Jordan PH Jr, Barroso A, Sweeney J: Gastric carcinoids in patients with hypergastrin- emia. J Am Coll Surg 2004; 199: 552-555.
- Rindi G, Bordi C, Rappel S, et al: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-172.
- Landry CS, Brock G, Scoggins CR, et al: A proposed staging system for gastric carci- noid tumors based on an analysis of 1,543 patients. Ann Surg Oncol 2009; 16: 51-60.
- Schindl M, Kaserer K, Niederle B: Treatment of gastric neuroendocrine tumors: the neces- sity of a type-adapted treatment. Arch Surg 2001; 136: 49-54.
- Ichikawa J, Tanabe S, Koizumi W, et al: En- doscopic mucosal resection in the manage- ment of gastric carcinoid tumors. Endoscopy 2003; 35: 203-206.
- Hosokawa O, Kaizaki Y, Hattori M, et al: Long-term follow up of patients with multi- ple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005; 8: 42-46.
- Modlin IM, Lye KD, Kidd M: Carcinoid tu- mors of the stomach. Surg Oncol 2003; 12: 153-172.
- D'Adda T, Annibale B, Delle Fave G, et al: Oxyntic endocrine cells of hypergastrinae- mic patients: differential response to antrec- tomy or octreotide. Gut 1996; 38: 668-674.
- Dakin GF, Warner RR, Pomp A, et al: Pre- sentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93: 368-372.
- Campana D, Nori F, Pezzilli R, et al: Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15: 337-342.
- Manfredi S, Pagenault M, de Lajarte-Thir- ouard AS, et al: Type 1 and 2 gastric carci- noid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol 2007; 19: 1021-1025.
- Grozinsky-Glasberg S, Kaltsas G, Gur C, et al: Long-acting somatostatin analogues are an effective treatment for type 1 gastric car- cinoid tumours. Eur J Endocrinol 2008; 159: 475-482.
- Fykse V, Sandvik AK, Qvigstad G, et al: Treatment of ECL cell carcinoids with oc- treotide LAR. Scand J Gastroenterol 2004; 39: 621-628.
- Kokkola A, Sjöblom SM, Haapiainen R, et al: The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anae- mia: a prospective follow-up study. Scand J Gastroenterol 1998; 33: 88-92.
- Rappel S, Altendorf-Hofmann A, Stolte M: Prognosis of gastric carcinoid tumours. Di- gestion 1995; 56: 455-462.
- Annibale B, Marignani M, Azzoni C, et al: Atrophic body gastritis: distinct features as- sociated with Helicobacter pylori infection. Helicobacter 1997; 2: 57-64.
- Lahner E, Bordi C, Di Giulio E, et al: Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Ali- ment Pharmacol Ther 2002; 16: 507-514.
- Bordi C, Azzoni C, Pilato FP, et al: Mor- phometry of gastric endocrine cells in hyper- gastrinemic patients treated with the soma- tostatin analogue octreotide. Regul Pept 1993; 47: 307-318.
- Peghini PL, Annibale B, Azzoni C, et al: Ef- fect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastro- enterology 2002; 123: 68-85.
- Berna MJ, Annibale B, Marignani M, et al: A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93: 1582-1591.
- Dixon MF, Genta RM, Yardley JH, et al: Classification and grading of gastritis. The Updated Sydney System. International Workshop on the Histopathology of Gastri- tis, Houston 1994. Am J Surg Pathol 1996; 10: 1161-1181.
- Lahner E, Caruana P, D'Ambra G, et al: First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done? Gastrointest Endosc 2001; 53: 443-448.
- Lahner E, Centanni M, Agnello G, et al: Oc- currence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med. 2008; 121: 136-141.
- Ruszniewski P, Delle Fave G, Cadiot G, et al: Well-differentiated gastric tumors/carcino- mas. Neuroendocrinology 2006; 84: 158-164.
- Johnson FE, Smith JB, Janney CM et al: Mul- tiple gastric carcinoids. J Am Coll Surg 2003; 196: 984-985.
- Hsing AW, Hansson LE, McLaughin JK, et al: Pernicious anemia and subsequent cancer: a population based cohort study. Cancer 1993; 71: 745-750.
- De Vries AC, Van Grieken NC, Looman CW, et al: Gastric cancer risk in patients with pre- malignant gastric lesions: a nationwide co- hort study in the Netherlands. Gastroenter- ology 2008; 134: 945-952.
- Bordi C, Azzoni C, Ferraro G, et al: Sam- pling strategies for analysis of enterochro- maffin-like cell changes in Zollinger-Elli- son Syndrome. Am J Clin Pathol 2000; 114: 419-425.
- 10.1210%2fjc.81.2.677 · doi:10.1210/jc.81.2.677
- 10.1210%2fjc.86.5.2236 · DOI
Cited by
AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review
Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.078 · Cited by 560
ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms
Delle Fave, G., O''Toole, D., Sundin, A., Taal, B., Ferolla, P., Ramage, J. K., Ferone, D., Ito, T., Weber, W., Zheng-Pei, Z., et al. (2016) · Neuroendocrinology · doi:10.1159/000443168 · Cited by 495
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms
Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P. (2012) · Neuroendocrinology · doi:10.1159/000335595 · Cited by 327
S2k-Leitlinie Neuroendokrine Tumore: AWMF-Reg. 021-27
Authors, Collaborators:, Deutsche Gesellschaft für Gastroenterologie, V. U. S. (., (Patientenvertretung), N. N. T. (. E. V., (Patientenvertretung), B. S. N. T. E. V. (.-S., Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), U. A. I. O. (. D. D. K. E. V., (DGAV), D. G. F. A. U. V. E. V., (DGCH), D. G. F. C., (DGEBV), D. G. F. E. U. B. V., (DGNM), D. G. F. N. E. V., et al. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0604-2924 · Cited by 180
Review article: the investigation and management of gastric neuroendocrine tumours
Basuroy, R., Srirajaskanthan, R., Prachalias, A., Quaglia, A., & Ramage, J. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12698 · Cited by 180
“Nonlesion gastric biopsies identify atrophy in 82% of patients, with severe atrophy found in 64%.(45) Gastric pH testing (>4) can help differentiate type 1 GCs in cases where atrophy is not readily demonstrated.”
BackgroundAutoimmune gastritis: histology phenotype and OLGA staging
Rugge, M., Fassan, M., Pizzi, M., Zorzetto, V., Maddalo, G., Realdon, S., de Bernard, M., Betterle, C., Cappellesso, R., Pennelli, G., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05101.x · Cited by 134
Fossmark, R., Sørdal, Ø. F., Jianu, C. S., Qvigstad, G., Nordrum, I. S., Boyce, M. J., & Waldum, H. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12090 · Cited by 110
“Type 1 GC may be removed endoscopically, but recurrence occurs in the majority of patients.(17) Radical resection may be difficult to achieve because many tumours invade the submucosa and the frequent multifocality of type 1 GC makes other treatment strategies necessary in many patients.”
BackgroundUpdate on gastroenteropancreatic neuroendocrine tumors
Andreasi, V., Partelli, S., Muffatti, F., Manzoni, M. F., Capurso, G., & Falconi, M. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.08.031 · Cited by 105
Self-citationLahner, E., Esposito, G., Pilozzi, E., Purchiaroni, F., Corleto, V. D., Di Giulio, E., & Annibale, B. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1010570 · Cited by 97
“A recent study on endoscopic management of these tumors, reported that for AG patients without recurring type I gastric carcinoids, endoscopic controls might be planned yearly in the early follow up but can probably become less intensive with endoscopic controls every 4 years according to AG screening for gastric canc…”
BackgroundMethodSelf-citationVanoli, A., Rosa, S. L., Miceli, E., Klersy, C., Maragliano, R., Capuano, F., Persichella, A., Martino, M., Inzani, F. S., Luinetti, O., et al. (2018) · Neuroendocrinology · doi:10.1159/000489902 · Cited by 88
Self-citationCurrent Concepts on Gastric Carcinoid Tumors
Nikou, G. C., & Angelopoulos, T. P. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/287825 · Cited by 78
“The European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines have recently suggested that annual surveillance is appropriate when dealing with patients with GC-I less than 10 mm in size (Figure 4) [44].”
BackgroundGastric and duodenal neuroendocrine tumours
O’Toole, D., Fave, G. D., & Jensen, R. T. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.002 · Cited by 76
“Endoscopic resection can be easily repeated provided tumours do not grow beyond T1 [3,96] and this strategy appears to be universally accepted Nonetheless, recurrences do occur and a recurrence rate in a recent series of patients treated endoscopically was 64% (21/33) at a median of eight months and of these, 67% (14/…”
BackgroundGastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli, F., Zilli, A., Conte, D., Ciafardini, C., & Massironi, S. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1054426 · Cited by 73
“Such neoplasms are mostly multiple (65% of cases) with a median 5-mm diameter [6], they are usually benign and well-differentiated, with Ki-67 <1% (NET G1) [4].”
BackgroundBoyce, M. J., Moore, A. R., Sagatun, L., Parsons, B. N., Varró, A., Campbell, F., Fossmark, R., Waldum, H. L., & Pritchard, D. M. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13146 · Cited by 71
Sato, Y., Imamura, H., Kaizaki, Y., Koizumi, W., Ishido, K., Kurahara, K., Suzuki, H., Fujisaki, J., Hirakawa, K., Hosokawa, O., et al. (2013) · Digestive Endoscopy · doi:10.1111/den.12197 · Cited by 69
Moore, A. R., Boyce, M. J., Steele, I. A., Campbell, F., Varró, A., & Pritchard, D. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076462 · Cited by 68
“Tumours <1 cm diameter rarely metastasise, have a good prognosis, and are usually managed by endoscopic surveillance or resection [6-11].”
BackgroundEndoscopic submucosal dissection for foregut neuroendocrine tumors: An initial study
Li, Q. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i40.5799 · Cited by 67
Long-term results of endoscopic resection for type I gastric neuroendocrine tumors
Uygun, A., Kadayifci, A., Polat, Z., Yilmaz, K., Gunal, A., Demir, H., & Bagci, S. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23477 · Cited by 62
“[21] reported the success of endoscopic removal for Type 1 gastric carcinoids in a recent prospective trial.”
BackgroundGastric neuroendocrine neoplasms
Lamberti, G., Panzuto, F., Pavel, M. E., O’Toole, D., Ambrosini, V., Falconi, M., García‐Carbonero, R., Riechelmann, R. P., Rindi, G., & Campana, D. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00508-y · Cited by 62
“If there is a single tumour or a small number of tumours, endoscopic mucosal resection, modified endoscopic mucosal resection, submucosal dissection or full-thickness endoscopic resection can be performed 109,110 .”
Self-citationGastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis
Tsolakis, A. V., Ragkousi, A., Vujasinović, M., Kaltsas, G., & Daskalakis, K. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i35.5376 · Cited by 60
Grozinsky‐Glasberg, S., Alexandraki, K., Angelousi, A. G., Chatzellis, E., Sougioultzis, S., & Kaltsas, G. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.04.013 · Cited by 60
Campana, D., Ravizza, D., Ferollà, P., Faggiano, A., Grimaldi, F., Albertelli, M., Berretti, D., Castellani, D., Cacciari, G., Fazio, N., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0584-z · Cited by 51
“The current literature points out the elevated variability which exists between treatments in cases of multiple, localized (mucosa or submucosa) type I gNENs: (1) careful endoscopic follow-up without any treatment [12–14], (2) somatostatin analog (SSA) therapy [9, 15, 16] and (3) endoscopic resection [10, 17].”
BackgroundChung, C., Tsai, C.-L., Chu, Y., Chen, K., Lin, J., Chen, B., Sun, W., Yen, H., Chen, C., Wu, I., et al. (2018) · Medicine · doi:10.1097/md.0000000000012101 · Cited by 50
Endoscopic diagnosis and management of type I neuroendocrine tumors
Sato, Y. (2015) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v7.i4.346 · Cited by 48
Crosby, D. A., Donohoe, C. L., Fitzgerald, L. M., Muldoon, C., Hayes, B. D., O’Toole, D., & Reynolds, J. V. (2012) · Digestive Surgery · doi:10.1159/000342988 · Cited by 46
Gastric neuroendocrine neoplasms: A review
Köseoğlu, H., Düzenli, T., & Sezikli, M. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i27.7973 · Cited by 45
Panzuto, F., Parodi, M. C., Esposito, G., Massironi, S., Fantin, A., Cannizzaro, R., Milione, M., Angelis, C. G. D., & Annibale, B. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.12.015 · Cited by 43
Self-citationBoyce, M. J., & Thomsen, L. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1009941 · Cited by 43
“Regular endoscopic surveillance is appropriate in some patients with types 1 and 2; endoscopic resection of multiple tumors may be difficult, and recurrence occurs in most patients [87].”
BackgroundMassironi, S., Zilli, A., Fanetti, I., Ciafardini, C., Conte, D., & PERACCHI, M. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.07.155 · Cited by 43
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)
Effraimidis, G., Knigge, U., Rossing, M., Oturai, P., Rasmussen, Å. K., & Feldt‐Rasmussen, U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.011 · Cited by 42
Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre study
Esposito, G., Cazzato, M. T., Rinzivillo, M., Pilozzi, E., Lahner, E., Annibale, B., & Panzuto, F. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.11.012 · Cited by 41
Self-citationDiagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors
Chin, J. L., & O’Toole, D. (2017) · Clinical Endoscopy · doi:10.5946/ce.2017.181 · Cited by 41
Chen, W., Zhou, P., Li, Q., Xu, M., & Yao, L.-Q. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/869769 · Cited by 40
Gastric Carcinoids (Neuroendocrine Neoplasms)
Kidd, M. S., Gustafsson, B. I., & Modlin, I. M. (2013) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2013.01.009 · Cited by 40
Systematic review: management of localised low‐grade upper gastrointestinal neuroendocrine tumours
Exarchou, K., Howes, N., & Pritchard, D. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15765 · Cited by 39
Rossi, R. E., Invernizzi, P., Mazzaferro, V., & Massironi, S. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640619890465 · Cited by 36
“Therapeutic strategies for gNET-1s are based on risk stratification according to tumor size, lesion number, stage, and grade.(14,18,34,41,47) According to the current guidelines from the ENETS, endoscopic management with lesion resection(3) represents the gold standard for gNET-1s that do not infiltrate the muscularis…”
MethodGastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy—A literature review
Berardi, R., Rinaldi, S., Torniai, M., Morgese, F., Partelli, S., Caramanti, M., Onofri, A., Polenta, V., Pagliaretta, S., Falconi, M., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.003 · Cited by 33
“For polyps over 2 cm dimensioned, or invading beyond the submucosa, or if there are positive resection margins, multiple tumors >1 cm, or regional lymph node metastasis, local antrectomy or total gastrostomy should be performed (Delle Fave et al., 2012; Merola et al., 2012).”
BackgroundPanzuto, F., Magi, L., Esposito, G., Rinzivillo, M., & Annibale, B. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6679397 · Cited by 33
“Two studies [16, 19] focused on long-term outcomes, and the recurrence rate was the main endpoint.”
BackgroundMethodInfluentialSelf-citationGastric cancer in patients with type I gastric carcinoids
Lahner, E., Esposito, G., Pilozzi, E., Galli, G., Corleto, V. D., Giulio, E. D., & Annibale, B. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0393-8 · Cited by 33
“mucosal carcinoids, every 6–12 months after diagnosis is suggested; this approach seems safe for T1-GCs [1, 9, 36].”
BackgroundSelf-citationLipiński, M., Rydzewska, G. M., Fołtyn, W., Andrysiak-Mamos, E., Bałdys‐Waligórska, A., Bednarczuk, T., Blicharz-Dorniak, J., Bolanowski, M., Boratyn-Nowicka, A., Borowska, M., et al. (2017) · Endokrynologia Polska · doi:10.5603/ep.2017.0016 · Cited by 34
Management and Disease Outcome of Type I Gastric Neuroendocrine Tumors: The Mount Sinai Experience
Chen, W., Warner, R. R. P., Ward, S. C., Harpaz, N., Divino, C. M., Itzkowitz, S. H., & Kim, M. K. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3410-1 · Cited by 32
Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms
Kaltsas, G., Grozinsky‐Glasberg, S., Alexandraki, K., Thomas, D., Tsolakis, A. V., Gross, D., & Grossman, A. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12476 · Cited by 32
Management of gastric neuro-endocrine tumours in a large French national cohort (GTE)
Manfrédi, S., Walter, T., Baudin, É., Coriat, R., Ruszniewski, P. B., Lecomte, T., Laurenty, A.-P., Goichot, B., Rohmer, V., Roquin, G., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1355-9 · Cited by 32
Exarchou, K., Hu, H., Stephens, N. A., Moore, A. R., Kelly, M., Lamarca, Á., Mansoor, W., Hubner, R. A., McNamara, M. G., Smart, H. L., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03143-3 · Cited by 29
Chin, J. L., O'Connell, J. E. A., Muldoon, C., Swan, N., Reynolds, J. V., Ravi, N., Geoghegan, J., Conlon, K. C., O'Shea, D. B., & O’Toole, D. (2020) · Digestive Surgery · doi:10.1159/000510962 · Cited by 27
Lahner, E., Pilozzi, E., Esposito, G., Galli, G., & Annibale, B. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.878381 · Cited by 27
Self-citationLaffi, A., Lania, A. G., Ragni, A., Vito, V. D., Liccardi, A., Rubino, M., Sesti, F. F., Colao, A. A. L., Faggiano, A., & on behalf of the NIKE Group (2023) · Cancers · doi:10.3390/cancers15082202 · Cited by 27
“The lesions are often multiple in number and are characterized by indolent behavior (metastases in 0–2% of cases) [6,7].”
BackgroundRossi, R. E., Elvevi, A., Gallo, C., Palermo, A., Invernizzi, P., & Massironi, S. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i26.3258 · Cited by 25
A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?
Postlewait, L. M., Baptiste, G. G., Ethun, C. G., Le, N., Cardona, K., Russell, M. C., Willingham, F. F., Kooby, D. A., Staley, C. A., & Maithel, S. K. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24369 · Cited by 25
“After resection of these Type I tumors, recurrence is common and occurred in55%ofpatients in thecurrent series (18–64%inother series),with a3-year recurrence-free survival of33%[26,27].”
BackgroundGastric neuroendocrine neoplasias: manifestations and comparative outcomes
Felder, S., Jann, H., Arsenić, R., Denecke, T., Prasad, V., Knappe-Drzikova, B., Maasberg, S., Wiedenmann, B., Pavel, M. E., Pascher, A., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0582 · Cited by 26
“Gastric neuroendocrine neoplasias (gNENs) are a heterogeneous subgroup of gastroenteropancreatic neuroendocrine neoplasias (GEP-NENs) derived from specialized cells of the diffuse endocrine system and were initially described as gastric carcinoids by Max Askanazy, who already noted their similarity to the carcinoid tu…”
ResultSomatostatin analogs for gastric carcinoids: For many, but not all
Massironi, S., Zilli, A., & Conte, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6785 · Cited by 25
Grimaldi, F., Fazio, N., Attanasio, R., Frasoldati, A., Papini, E., Angelini, F., Baldelli, R., Berretti, D., Bianchetti, S., Bizzarri, G., et al. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0119-0 · Cited by 23
Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management
Panzuto, F., Massironi, S., Partelli, S., Campana, D., Rinzivillo, M., Invernizzi, P., Andreasi, V., Lamberti, G., & Falconi, M. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.08.015 · Cited by 23
Self-citationEsposito, G., Dell’Unto, E., Ligato, I., Marasco, M., & Panzuto, F. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2242261 · Cited by 22
Self-citationNamikawa, K., Kamada, T., Fujisaki, J., Sato, Y., Murao, T., Chiba, T., Kaizaki, Y., Ishido, K., Ihara, Y., Kurahara, K., et al. (2023) · Digestive Endoscopy · doi:10.1111/den.14529 · Cited by 21
Calvete, O., Varró, A., Pritchard, D. M., Barroso, A., Oteo, M., Morcillo, M. Á., Vargiu, P., Dodd, S., Garcia, M. M., Reyes, J., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025890 · Cited by 21
“(Merola et al., 2012).”
Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may targetDUSP1
Dou, D., Shi, Y., Liu, Q., Luo, J., Liu, J., Liu, M., Liu, Y., Li, Y., Qiu, X.-D., & Tan, H. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i5.573 · Cited by 21
Atrophic gastritis and pre-malignant gastric lesions
Lahner, E., Esposito, G., Galli, G., & Annibale, B. (2015) · Translational gastrointestinal cancer · Cited by 20
Self-citationLahner, E., Hassan, C., Esposito, G., Carabotti, M., Zullo, A., Dinis-Ribeiro, M. J., & Annibale, B. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.004 · Cited by 19
Self-citationEndoscopic techniques for gastric neuroendocrine tumors: An update
Massironi, S., Gallo, C., Laffusa, A., Ciuffini, C., Conti, C. B., Barbaro, F., Boškoski, I., Dinelli, M. E., & Invernizzi, P. (2023) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v15.i3.103 · Cited by 18
Endoscopic Treatment for Early Foregut Neuroendocrine Tumors
Park, M. I. (2013) · Clinical Endoscopy · doi:10.5946/ce.2013.46.5.450 · Cited by 18
Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study
Chen, Y., Guo, W., Shi, Y., Su, F., Yu, F., Chen, R., Wang, C., Liu, J., Luo, J., & Tan, H. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03079-6 · Cited by 18
“The recurrence rate after endoscopic treatment is as high as 56.9–63.6% according to previous reports, and the median recurrence time is 8–39 months [18, 19, 29, 30].”
BackgroundInfluentialManagement of Gastric Carcinoids (Neuroendocrine Neoplasms)
Kidd, M. S., & Gustafsson, B. I. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0289-x · Cited by 16
Massironi, S., Oriani, E., Dell’Anna, G., Danese, S., & Facciotti, F. (2025) · Cells · doi:10.3390/cells14201576 · Cited by 15
“Although gNENs associated with AIG are generally indolent and carry a favorable prognosis [78], their multifocality and tendency for recurrence require endoscopic monitoring [79,80].”
Kim, Y., Ahn, B., Choi, K. D., Kim, B. S., Yook, J. H., Lee, G. H., Hong, S., & Lee, J. H. (2023) · Gut and Liver · doi:10.5009/gnl220175 · Cited by 13
Endoskopische Therapie gastroduodenaler neuroendokriner Neoplasien
Maasberg, S., Jürgensen, C., Scheerer, F., Pschowski, R., Felder, S., Begum, N., Wiedenmann, B., Pascher, A., & Pape, U. (2016) · Der Chirurg · doi:10.1007/s00104-016-0157-6 · Cited by 13
Rydzewska, G. M., Cichocki, A. S., Ćwikła, J. B., Fołtyn, W., Hubalewska–Dydejczyk, A., Kamiński, G., Lewczuk, A., Nasierowska-Guttmejer, A. M., Nowakowska-Duława, E., Pilch-Kowalczyk, J., et al. (2014) · Endokrynologia Polska · doi:10.5603/ep.2013.0030 · Cited by 13
“The course of the disease is usually mild, and after endoscopic or surgical treatment it only requires a periodic endoscopic surveillance [6].”
InfluentialFollow-up of patients with ECL cell-derived tumours
Sagatun, L., Fossmark, R., Jianu, C. S., Qvigstad, G., Nordrum, I. S., Mjønes, P., & Waldum, H. L. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2016.1169588 · Cited by 12
“[28] The GCs in our population were small and multicentric, as described in other case series.[27,29] They demonstrated a low-proliferative index and most of them were diagnosed in stage I, as reported in other follow-ups of ECL cell neoplasms.”
ResultGastric neuroendocrine tumors: 20‐Year experience in a reference center
Ravizza, D., Giunta, M., Sala, I., Bagnardi, V., Tamayo, D., Roberto, G. D., Trovato, C. M. C., Bravi, I., Soru, P., Maregatti, M., et al. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13440 · Cited by 11
“26,31 None of the Type 3 gNET patients we managed endoscopically developed local recurrence or metachronous lesions.”
Management of type I gastric-neuroendocrine tumors: the less the better?
Rossi, R. E., Masoni, B., Poletti, V., Maselli, R., Carrara, S., Bertuzzi, A. F., Uccella, S., Lania, A. G., Zerbi, A., Hassan, C., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1666699 · Cited by 11
“…is technically complex due to the frequent coexistence of multiple concomitant gNETs, which can be characterized by small size or even be intramucosal NETs, and metachronous lesions that continuously develop in the context of dyschromic metaplastic mucosa, which is pre-cancerous in nature (24).”
Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?
Cavalcoli, F., Gallo, C., Coltro, L. A., Rausa, E., Cantù, P., Invernizzi, P., & Massironi, S. (2023) · Medicina · doi:10.3390/medicina59101757 · Cited by 11
“…number of recurrences reported in the literature, excisional biopsy and simple snare polypectomy should not been performed with therapeutic intent [34]. and/or >20 mm lesions should undergo complete staging through EUS, CT-scan/MRI, GNENs larger than 10–15 mm and/or non-low G2 lesions, either…”
BackgroundInfluentialMalczewska, A., Procner, A., Walter, A., Kuśnierz, K., Zajęcki, W., Aslanian, H. R., & Kos‐Kudła, B. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01348-2 · Cited by 11
Gastric neuroendocrine tumors: management and challenges
Kwon, D. H.-M., Nakakura, E. K., Bergsland, E. K., & Dai, S.-C. (2017) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s109028 · Cited by 10
Li, Y., Wu, Z.-Q., Xu, Q., Goyal, H., & Xu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681149 · Cited by 10
Papaefthymiou, A., Laskaratos, F., Koffas, A., Manolakis, A. C., Gkolfakis, P., Coda, S., Sodergren, M. H., Suzuki, N., & Toumpanakis, C. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00986-w · Cited by 10
Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study
Sheikh‐Ahmad, M., Saiegh, L., Shalata, A., Bejar, J., Shefer, H. K., Sirhan, M. F., Matter, I., Swaid, F., Laniado, M., Mubariki, N., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030828 · Cited by 10
Endoscopy and Endoscopic Ultrasound in Assessing and Managing Neuroendocrine Neoplasms
O’Toole, D., & Palazzo, L. (2015) · Frontiers of hormone research · doi:10.1159/000382062 · Cited by 11
Merola, E., Michielan, A., Rozzanigo, U., Erini, M., Sferrazza, S., Marcucci, S., Sartori, C., Trentin, C., de Pretis, G., & Chierichetti, F. (2022) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v14.i2.78 · Cited by 8
Self-citationEndoscopic resection for gastrointestinal neuroendocrine tumors
Boškoski, I., Volkanovskа, A., Tringali, A., Bove, V., Familiari, P., Perri, V., & Costamagna, G. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.816117 · Cited by 8
How should incidental NEN of the pancreas and gastrointestinal tract be followed?
Ariotti, R., Partelli, S., Muffatti, F., Andreasi, V., Sala, F. D., & Falconi, M. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9445-4 · Cited by 8
Moore, A. R., Boyce, M. J., Steele, I. A., Campbell, F., Varró, A., & Pritchard, D. M. (2013) · PLoS ONE · doi:10.1371/annotation/4afd48b1-8dc0-47cc-9c8a-99aba7623116 · Cited by 8
Wang, M., Shubang, C., Zhu, L., Xu, T., Zhang, J., Zhang, Y., Ping, J., & Wang, R. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07143-7 · Cited by 7
Huang, J., Liu, H., Yang, D., Xu, T., Wang, J., & Li, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003029 · Cited by 6
“[10] In this study, 78 (83.0”
BackgroundInfluentialSagatun, L., Mjønes, P., Jianu, C. S., Boyce, M. J., Waldum, H. L., & Fossmark, R. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000713 · Cited by 6
Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
Sebastián‐Valles, F., Madrid, B. B., Ganga, C. S. L., Carrillo-López, E., Carreiro, S. M., Antón, L. Á., García, N. S.-M., Sampedro-Nuñez, M. A., Pérez, J. Á. D., & Marazuela, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030872 · Cited by 6
“metastasis-free survival at 4 years follow-up, but with tumor recurrence rates of 60% [43].”
BackgroundAdvances in the diagnosis and treatment of gastric neuroendocrine neoplasms
Tan, H. (2016) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2016.11.03 · Cited by 6
“The prognosis is often good and metastasis is rarely seen, although recurrence is common (19,20).”
BackgroundChen, Y., Han, D., Zhu, J., Chen, J., Hu, H., Dou, D., Wang, X., Yuan, B., Wang, C., Qi, Z., et al. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735420958488 · Cited by 7
Autoimmune gastritis: from symptom to diagnosis. Clinical observations
Livzan, M. A., Сергеевна, К. Т., Игоревич, М. С., Kostoglod, T. V. K., & Kostoglod, А. V. K. (2020) · Consilium Medicum · doi:10.26442/20751753.2020.8.200037 · Cited by 6
Five Autoimmune Gastritis Patients with Positive Findings of Serum Anti-parietal Cell Antibodies
Jeong, J. H., Lee, S., Han, H. S., Kim, J. H., Sung, I., & Park, H. S. (2021) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2021.0016 · Cited by 6
“약 8개월 후에 60% 에서 재발되지만 다시 내시경으로 절제하면 예후는 좋다.(28) 종 양이 많아서 내시경으로 절제할 수 없을 때는 가스트린 분비를 줄이기 위해 전정부 절제술을 고려하거나 somatostatin 유사체 (octreotide, lanreotide, pasireotide)를 주사한다.”
Kubo, K., Kimura, N., Matsuda, S., Mabe, K., & Kato, M. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2679-19 · Cited by 5
Multicentric Type 3 Gastric Neuroendocrine Tumors
Lee, S. H., Moon, D., Lee, H. S., Lee, C., Jeon, Y. D., Park, J. H., Kim, H., & Lee, S. K. (2015) · Clinical Endoscopy · doi:10.5946/ce.2015.48.5.431 · Cited by 5
“Endoscopically, type 1 gastric NET tumors are often found in the fundus of stomach and are mostly polypoid (78%), of small shape (size 5 to 8 mm), and are multicentric (68%; mean number, 3).(11,12) Type 2 gastric NETs are also usually identified as small, often multiple, polypoid tumors (<1 cm in size) in fundus.”
BackgroundRydzewska, G. M., Strzelczyk, J., Bednarczuk, T., Bolanowski, M., Borowska, M., Chmielik, E., Ćwikła, J. B., Fołtyn, W., Gisterek, I., Handkiewicz-Junak, D., et al. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0051 · Cited by 5
Ogata, Y., Hatta, W., Kanno, T., Saito, M., Jin, X., Asano, N., Koike, T., Imatani, A., Yuan, Y., & Masamune, A. (2025) · Digestive Endoscopy · doi:10.1111/den.15026 · Cited by 4
Modern Management of Gastric Neuroendocrine Neoplasms
Kunstman, J. W., Nagar, A. B., Gibson, J. A., & Kunz, P. L. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01207-2 · Cited by 4
“Management strategies for gastrinoma are discussed in detail elsewhere [24, 26, 35].”
How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery
Fermi, F., Andreasi, V., Muffatti, F., Crippa, S., Tamburrino, D., Partelli, S., & Falconi, M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01200-8 · Cited by 4
Shamiyeh, A., & Gabriel, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15608 · Cited by 4
Clinicopathological features of primary gastric neuroendocrine neoplasms: A single‐center analysis
Xu, T. M., Wang, C. S., Jia, C.-W., Qian, J., & Li, J. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12326 · Cited by 4
Recurrent gastric neuroendocrine tumors treated with total gastrectomy
Jung, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i46.13195 · Cited by 4
Yang, Z.-L., Wang, H., Liu, Y., Dou, L., Zhang, Y.-M., Ng, H., He, S., Chi, Y., & Wang, G.-Q. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i8.114268 · Cited by 3
“Studies have shown that the recurrence rate of G-NETs after endoscopic treatment ranges from 2.4% to 63.6%[18,20,21,25].”
InfluentialGastrointestinal Surgery of Neuroendocrine Neoplasms
Hansen, C. P., Olsen, I. H., & Knigge, U. (2015) · Frontiers of hormone research · doi:10.1159/000382144 · Cited by 3
Metadata
- Authors
- Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., & Delle Fave, G.
- Affiliations
- Azienda Ospedaliera Sant'Andrea (IT)
- University of Parma (IT)
- ORCID
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2011-07-30
- Volume
- 95
- Issue
- 3
- Pages
- 207-213
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W1970633635
- Cited by
- 132
- References
- 44
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 13 · 2022: 6 · 2021: 12 · 2020: 8 · 2019: 5 · 2018: 8 · 2017: 5 · 2016: 12 · 2015: 15 · 2014: 12 · 2013: 8 · 2012: 9
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Funders
- Ministero dell'Università e della Ricerca
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- enterochromaffin-like cells, neuroendocrine neoplasms, atrophic gastritis, endoscopic resection, tumor recurrence, recurrence-free survival, risk factors, gastric polyps
- MeSH terms
- Adult, Aged, Aged, 80 and over, Carcinoid Tumor, Endoscopy, Female, Follow-Up Studies, Gastritis, Atrophic, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Risk Factors, Stomach Neoplasms, Survival Rate, Proportional Hazards Models, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.